MYOS Co. (NASDAQ:MYOS) was up 9% during trading on Friday . The stock traded as high as $1.44 and last traded at $1.33. Approximately 157,410 shares were traded during mid-day trading, an increase of 260% from the average daily volume of 43,676 shares. The stock had previously closed at $1.22.
The company has a current ratio of 3.53, a quick ratio of 2.06 and a debt-to-equity ratio of 0.04. The company has a market cap of $11.56 million, a P/E ratio of -2.95 and a beta of 0.61.
MYOS (NASDAQ:MYOS) last issued its earnings results on Wednesday, May 8th. The company reported ($0.13) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.14) by $0.01. MYOS had a negative net margin of 660.40% and a negative return on equity of 86.64%. The company had revenue of $0.15 million for the quarter, compared to the consensus estimate of $0.10 million. On average, equities research analysts forecast that MYOS Co. will post -0.5 earnings per share for the current year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Pinnacle Associates Ltd. bought a new stake in shares of MYOS in the 4th quarter valued at about $172,000. Murphy Capital Management Inc. bought a new stake in shares of MYOS in the 1st quarter valued at about $32,000. Finally, Community Capital Management Inc. bought a new stake in shares of MYOS in the 1st quarter valued at about $57,000. Institutional investors and hedge funds own 5.03% of the company’s stock.
TRADEMARK VIOLATION NOTICE: This news story was originally published by Community Financial News and is the sole property of of Community Financial News. If you are reading this news story on another site, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright legislation. The legal version of this news story can be accessed at https://www.com-unik.info/2019/06/14/myos-nasdaqmyos-trading-up-9.html.
MYOS Company Profile (NASDAQ:MYOS)
MYOS RENS Technology Inc, a bionutrition and biotherapeutics company, focuses on the discovery, development, and commercialization of nutritional and therapeutic products for maintaining and enhancing the health and performance of muscle tissue. The company primarily focuses on developing the products that enhance muscle health and function essential to the management of sarcopenia, cachexia, and degenerative muscle diseases, and as an adjunct to the treatment of obesity.
Read More: Hedge Funds
Receive News & Ratings for MYOS Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MYOS and related companies with MarketBeat.com's FREE daily email newsletter.